Shares of Gilead (GILD), a leader in the hepatitis C virus treatment space, are sliding this morning after one competitor’s hep C drug was granted FDA approval and another...
Today is the last day of the first month of the year. I favor monthly charts over weekly and weekly charts over daily. Wanted to take a long-term view of the Nasdaq 100 on a monthl...
The US dollar seems to be on the back foot following a cautious FOMC statement and poor data. BNP Paribas says dollar bulls can keep the faith: Here is their view, courtesy of e...
Inovio Pharmaceuticals (INO) shares are rising again this morning as the Zika virus continues to gain attention and its CEO says the company is “ahead of the pack” in d...
With the final trading day of January upon us, it’s time once again, to outline my potential stock buys for the upcoming month. The point of these posts is to help take some of t...
The Dow needs a closing above 16350 to stabilize for now temporarily. Otherwise, we are not out of the woods here until we pass March. To suggest that the major low has been made,...
In a move which appears to have caught most financial analysts by surprise, the Bank of Japan has moved its interest rate into negative territory, to the tune of minus 0.1%. This m...
A New York Times op-ed piece from earlier this week has reignited discussion about housing and the Federal Reserve as factors in the 2008-2009 Great Recession. Minds will differ ...
It is safe to say that nobody expected the BOJ stunner announced last night, when Kuroda announced that Japan would become the latest country to unleash negative interest rates, fo...
The Bank of Japan surprised the market. It did not expand its asset purchase plan, which was the main focus of many market participants, including ourselves. Instead, followin...